These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 22067399)
1. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. Turner RM; Bell KJ; Morton RL; Hayen A; Francken AB; Howard K; Armstrong B; Thompson JF; Irwig L J Clin Oncol; 2011 Dec; 29(35):4641-6. PubMed ID: 22067399 [TBL] [Abstract][Full Text] [Related]
2. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. McCarthy WH; Shaw HM; Thompson JF; Milton GW Surg Gynecol Obstet; 1988 Jun; 166(6):497-502. PubMed ID: 3375961 [TBL] [Abstract][Full Text] [Related]
3. Follow-up schedules after treatment for malignant melanoma. Francken AB; Accortt NA; Shaw HM; Colman MH; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF Br J Surg; 2008 Nov; 95(11):1401-7. PubMed ID: 18844268 [TBL] [Abstract][Full Text] [Related]
4. Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma. Lim WY; Morton RL; Turner RM; Jenkins MC; Guitera P; Irwig L; Webster AC; Dieng M; Saw RPM; Low D; Low C; Bell KJL JAMA Dermatol; 2018 Apr; 154(4):420-427. PubMed ID: 29490373 [TBL] [Abstract][Full Text] [Related]
5. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365 [TBL] [Abstract][Full Text] [Related]
6. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Francken AB; Shaw HM; Accortt NA; Soong SJ; Hoekstra HJ; Thompson JF Ann Surg Oncol; 2007 Jun; 14(6):1924-33. PubMed ID: 17357855 [TBL] [Abstract][Full Text] [Related]
7. [Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up]. Francken AB; Thompson JF; Bastiaannet E; Hoekstra HJ Ned Tijdschr Geneeskd; 2008 Mar; 152(10):557-62. PubMed ID: 18402322 [TBL] [Abstract][Full Text] [Related]
8. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. Leiter U; Buettner PG; Eigentler TK; Bröcker EB; Voit C; Gollnick H; Marsch W; Wollina U; Meier F; Garbe C J Am Acad Dermatol; 2012 Jan; 66(1):37-45. PubMed ID: 21700361 [TBL] [Abstract][Full Text] [Related]
9. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345 [TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II. Lee JE; Lu M; Mansfield PF; Platsoucas CD; Reveille JD; Ross MI Cancer; 1996 Aug; 78(4):758-63. PubMed ID: 8756369 [TBL] [Abstract][Full Text] [Related]
11. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. Einwachter-Thompson J; MacKie RM Br J Dermatol; 2008 Aug; 159(2):337-41. PubMed ID: 18510665 [TBL] [Abstract][Full Text] [Related]
12. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Meyers MO; Yeh JJ; Frank J; Long P; Deal AM; Amos KD; Ollila DW Ann Surg Oncol; 2009 Apr; 16(4):941-7. PubMed ID: 19101766 [TBL] [Abstract][Full Text] [Related]
13. [Follow-up for cutaneous melanoma]. Kettelhack C Ther Umsch; 2008 Jun; 65(6):335-40. PubMed ID: 18622957 [TBL] [Abstract][Full Text] [Related]
14. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Uliasz A; Lebwohl M Int J Dermatol; 2007 Jun; 46(6):575-7. PubMed ID: 17550554 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with local recurrence of cutaneous malignant melanoma: a population-based study. Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Singnomklao T; Ringborg U Cancer; 1997 Oct; 80(8):1418-25. PubMed ID: 9338465 [TBL] [Abstract][Full Text] [Related]
16. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year. Damude S; Hoekstra-Weebers JE; Francken AB; Ter Meulen S; Bastiaannet E; Hoekstra HJ Ann Surg Oncol; 2016 Sep; 23(9):2762-71. PubMed ID: 27194552 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531 [TBL] [Abstract][Full Text] [Related]
18. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Moore Dalal K; Zhou Q; Panageas KS; Brady MS; Jaques DP; Coit DG Ann Surg Oncol; 2008 Aug; 15(8):2206-14. PubMed ID: 18512102 [TBL] [Abstract][Full Text] [Related]